IP Verse

Compositions For Improving Cell Viability And Methods Of Use Thereof - EP2978419

The patent EP2978419 was granted to Amylyx Pharmaceuticals on Apr 15, 2020. The application was originally filed on Feb 24, 2014 under application number EP14775675A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2978419

AMYLYX PHARMACEUTICALS
Application Number
EP14775675A
Filing Date
Feb 24, 2014
Status
Opposition Rejected
Oct 21, 2022
Grant Date
Apr 15, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBJan 12, 2021LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBB -
BRUSCHETTINIJan 11, 2021PISTOLESI -

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2006050165
INTERNATIONAL-SEARCH-REPORTUS2009312297
INTERNATIONAL-SEARCH-REPORTUS2011142799
INTERNATIONAL-SEARCH-REPORTUS2012157419
OPPOSITIONEP2599477
OPPOSITIONWO2006050165
OPPOSITIONWO2009140265
OPPOSITIONWO2013142490
OPPOSITIONWO2014158547
SEARCHEP2599477
SEARCHWO2006050165
SEARCHWO2009140265

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- LIU NA et al., Journal ofNeurovirology, (20020000), vol. 8, no. 4, pages 318 - 325-
INTERNATIONAL-SEARCH-REPORT- ENGIN, F. ET AL., "Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases", DIABETES, OBESITY AND METABOLISM, (2010), vol. 12, no. 2 SUPP, pages 108 - 115, XP055279874
INTERNATIONAL-SEARCH-REPORT- MIKI, T. ET AL., "Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho- glycogen synthase kinase-3 beta -mediated suppression of mitochondrial permeability transition", DIABETES, (2009), vol. 58, no. 12, pages 2863 - 2872, XP055279871
OPPOSITION- B. BHANDARY et al., "An Involvement of Oxidative Stress in Endoplasmic Reticulum Stress and Its Associated Diseases", Int. J. Mol. Sci., (20130000), vol. 14, pages 434 - 456, XP055895897-
OPPOSITION- GROS-LOUIS, "In Vivo and In Vitro Models to Study Amyotrophic Lateral Sclerosis", Amyotrophic Lateral Sclerosis, (20120100), pages 82 - 124, XP055788452-
OPPOSITION- JEFFREY D. ROTHSTEIN, "Current Hypotheses for the Underlying Biology of Amyotrophic Lateral Sclerosis", Ann. Neurol, (20090000), vol. 65, pages S3 - S9, XP055788433-
OPPOSITION- JIM SCHNABEL, "Standard Model: Ouestions raised about the use of ''ALS mice'' are prompting a broad reappraisal of the way that drugs are tested in animal models of neurodegenerative disease", Standard Model, (20080000), pages 682 - 685, XP055788425-
OPPOSITION- Liu Na; Qiang Wenan; Kuang Xianghong; Thuillier Philippe; Lynn William S; Wong Paul K Y, "he peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidative cell death", Journal of Neurovirology, (20020700), vol. 8, no. 4, pages 318 - 325, XP009150465-
OPPOSITION- MARTIN H. MAURER, "Amyotrophic Lateral Sclerosis: An Introduction to Treatment and Trials", Amyotrophic Lateral Sclerosis: An Introduction to Treatment and Trials, (20120100), pages 1 - 40, XP055607277-
OPPOSITION- T. LANNITTI et al., "Clinical and Experimental Applications of Sodium Phenylbutyrate", Drugs R D, (20110000), vol. 11, no. 3, pages 227 - 249, XP055895893-
OPPOSITION- E. R. WHITTEMORE et al., "A detailed analysis of hydrogen peroxide-induced cell death in primary neuronal culture", Neuroscience, (19950800), vol. 67, no. 4, doi:10.1016/0306-4522(95)00108-U, pages 921 - 32, XP022262743
OPPOSITION- CLERC et al., "A look into the future of ALS research", Drug Discovery Today, (20160600), vol. 21, no. 6, doi:10.1016/j.drudis.2016.02.002, pages 939 - 949, XP029565571
OPPOSITION- CARRI et al., "Targets in ALS: designing multidrug therapies", Trends in Pharmacological sciences, (20060500), vol. 27, no. 5, doi:10.1016/j.tips.2006.03.009, XP025029564
OPPOSITION- 055309195 Hui Zhang; Shotaro Nakajima; Hironori Kato; Liubao Gu; Tatsuya Yoshitomi; Kaoru Nagai; Hideyuki Shinmori; Susumu Kokubo; Masanori Kitamura, "Selective , potent blockade of theIRE1 and ATF6 pathways by 4-phennylbutyric acid analogues", British Journal of Pharmacology, (20131001), vol. 170, no. 4, pages 882 - 834, XP055309195
OPPOSITION- F. ENGIN et al., "Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases", Diabetes, Obesity and Metabolism, (20100000), vol. 12, doi:10.1111/j.1463-1326.2010.01282.x, pages 108 - 115, XP055279874
OPPOSITION- R. J. TALLARIDA, "Quantitative Methods for Assessing Drug Synergism", Genes & Cancer, (20110000), vol. 2, no. 11, doi:10.1177/1947601912440575, pages 1003 - 1008, XP055206103
OPPOSITION- Ju-Hong Min; Yoon-Ho Hong; Jung-Joon Sung; Sung-Min Kim; Jung Bok Lee; Kwang-Woo Lee, "Oral Solubilized Ursodeoxycholic Acid Therapy in Amyotrophic Lateral Sclerosis: A Randomized Cross-Over Trial", J. Korean Med. Sci., (20120000), vol. 27, no. 2, pages 200 - 206, XP055434430
SEARCH- LIU NA ET AL, "The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidative cell death", JOURNAL OF NEUROVIROLOGY, INFORMA HEALTHCARE, GB, (20020101), vol. 8, no. 4, ISSN 1355-0284, pages 318 - 325, XP009150465 [Y] 1-15 * the whole document *-
SEARCH- SHARMA R ET AL, "Bile acid toxicity structure-activity relationships: Correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A)", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 18, no. 18, ISSN 0968-0896, (20100915), pages 6886 - 6895, (20100831), XP027252790 [A] 1-15 * abstract * * page 6886, column l, paragraph 1 - page 6888, column l, paragraph 1 * * page 6890, column l, paragraph 1 - page 6892, column r, paragraph 2 * * figure 2 *-
SEARCH- HUI ZHANG ET AL, "Selective, potent blockade of the IRE1 and ATF6 pathways by 4-phenylbutyric acid analogues", BRITISH JOURNAL OF PHARMACOLOGY, (20131001), vol. 170, no. 4, doi:10.1111/bph.12306, ISSN 0007-1188, pages 822 - 834, XP055309195 [YP] 1-15 * abstract * * page 823, column l, paragraph 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents